3M Poaches Zimmer Biomet CEO Hanson to Lead Healthcare Spinoff
By Colin Kellaher
3M has named Bryan Hanson chief executive of its healthcare spinoff, plucking the executive from musculoskeletal company Zimmer Biomet Holdings.
3M on Tuesday said Hanson will join the St. Paul, Minn., industrial conglomerate on Sept. 1 as CEO of its healthcare business group, which is being spun off as an independent company.
Hanson has been president and CEO of Zimmer Biomet since late 2017 and chairman since 2021.
Zimmer on Tuesday said Ivan Tornos, its chief operating officer since March 2021, takes the helm as president and CEO effective immediately and is also joining the Warsaw, Ind., company's board.
Zimmer said Suketu Upadhyay, who joined as executive vice president and chief financial officer in 2019, is taking on oversight of the company's global operations and supply-chain functions, while its lead independent director, Christopher Begley, succeeds Hanson as chairman.
3M in July 2022 unveiled plans to spin off the healthcare business, which had $8.4 billion in sales in 2022, joining the ranks of conglomerates using such moves to distinguish business lines with the potential for better sales and profit growth.
3M on Tuesday said healthcare industry veteran Carrie Cox will serve as chairman of spinoff.
Write to Colin Kellaher at colin.kellaher@wsj.com
Corrections & Amplifications
This article was corrected at 8:56 a.m. ET because it incorrectly said the plan to spin off the healthcare business was unveiled in June. In July 2022, MMM unveiled plans to spin off the healthcare business.
(END) Dow Jones Newswires
August 22, 2023 09:00 ET (13:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back